CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl. multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be
a) a guide for reporting for authors of RCTs,
b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a, 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.

Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):
Eysenbach G, CONSORT-EHEALTH Group
CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions
J Med Internet Res 2011;13(4):e126
URL: http://www.jmir.org/2011/4/e126/
doi: 10.2196/jmir.1923
PMID: 22209829

*Required

Your name *
First Last

Leanne Hides

Primary Affiliation (short), City, Country *
University of Toronto, Toronto, Canada

The University of Queensland, Brisbane

Your e-mail address *
abc@mail.com
Title of your manuscript *
Provide the (draft) title of your manuscript.
A web-based program for cannabis use and psychotic experiences in young people (Keep it Real): Protocol for a randomized controlled trial

Name of your App/Software/Intervention *
If there is a short and a long/alternate name, write the short name first and add the long name in brackets.
Keep it Real

Evaluated Version (if any)
e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

V2

Language(s) *
What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

English

URL of your Intervention Website or App
e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

https://www.keepitreal.org.au/login

URL of an image/screenshot (optional)

Your answer

Accessibility *
Can an enduser access the intervention presently?

- access is free and open
- access only for special usergroups, not open
- access is open to everyone, but requires payment/subscription/in-app purchases
- app/intervention no longer accessible
- Other:

Primary Medical Indication/Disease/Condition *
e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

Cannabis users with psychotic experiences
Primary Outcomes measured in trial *
comma-separated list of primary outcomes reported in the trial

Cannabis use, psychotic experiences

Secondary/other outcomes
Are there any other outcomes the intervention is expected to affect?

Other substance use and related-problems, PE-related distress, cannabis intoxication experiences, severity of cannabis dependence, depression/anxiety symptoms, suicidality, mental wellbeing, and functioning.

Recommended "Dose" *
What do the instructions for users say on how often the app should be used?

- Approximately Daily
- Approximately Weekly
- Approximately Monthly
- Approximately Yearly
- "as needed"
- Other: ____________________________

Approx. Percentage of Users (starters) still using the app as recommended after 3 months *

- unknown / not evaluated
- 0-10%
- 11-20%
- 21-30%
- 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71%-80%
- 81-90%
- 91-100%
- Other: ____________________________
Overall, was the app/intervention effective? *

- yes: all primary outcomes were significantly better in intervention group vs control
- partly: SOME primary outcomes were significantly better in intervention group vs control
- no statistically significant difference between control and intervention
- potentially harmful: control was significantly better than intervention in one or more outcomes
- inconclusive: more research is needed
- Other: This is a protocol paper

Article Preparation Status/Stage *
At which stage in your article preparation are you currently (at the time you fill in this form)

- not submitted yet - in early draft status
- not submitted yet - in late draft status, just before submission
- submitted to a journal but not reviewed yet
- submitted to a journal and after receiving initial reviewer comments
- submitted to a journal and accepted, but not published yet
- published
- Other: Trial is ongoing

Journal *
If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)
- JMIR mHealth and UHealth
- JMIR Serious Games
- JMIR Mental Health
- JMIR Public Health
Is this a full powered effectiveness trial or a pilot/feasibility trial? *
- Pilot/feasibility
- Fully powered

Manuscript tracking number *
If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)
- no ms number (yet) / not (yet) submitted to / published in JMIR
- Other: JRP ms#15803

TITe AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *
- yes
- Other:

1a-i) Identify the mode of delivery in the title
Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if intervention includes non-web-based internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.

|   | 1 | 2 | 3 | 4 | 5 | essential |
|---|---|---|---|---|---|-----------|
| subitem not at all important |   |   |   |   |   | essential |

Does your paper address subitem 1a-i? *
Copy and paste relevant sections from manuscript title (include quotes in quotation marks ‘like this’) to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The Keep it Real web-based" program for cannabis use and psychotic experiences in young people: Research protocol for a randomized controlled trial"
1a-ii) Non-web-based components or important co-interventions in title
Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").

Does your paper address subitem 1a-ii?
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
NA - there are no non-web-based components or co-interventions in the study

1a-iii) Primary condition or target group in the title
Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes")
Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

Does your paper address subitem 1a-iii? *
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
The Keep it Real web-based program for "cannabis use and psychotic experiences in young people": Research protocol for a randomized controlled trial

1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT
Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

Does your paper address subitem 1b-i? *
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

*Objective: To determine the efficacy and cost-effectiveness of the Keep it Real
web-based program, compared to an information-only control website among young cannabis users (16-25 years) with PEs.

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT
Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5
subitem not at all important
essential

Does your paper address subitem 1b-ii?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Both websites were self-guided/fully automated"

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT
Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed user group trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enroll). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5
subitem not at all important
essential

Does your paper address subitem 1b-iii?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this") to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants are recruited online and consenting individuals meeting inclusion criteria ((i) aged 16-25 years; who have (ii) used cannabis in the past month; and (iii) experienced PEs in the past 3 months) are automatically randomized to either the Keep it Real web-based program (n=249), or an information-only control website (n=249). Both websites are fully automated. The baseline and followed up assessments at 3, 6, 9, and 12 months post-baseline are self-completed online."

"Non-completers will be contacted via telephone to remind them to complete the survey online or over the phone" This information is reported in the method, not the abstract due to insufficient space.
1b-iv) RESULTS section in abstract must contain use data
Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

|     | 1   | 2   | 3   | 4   | 5   |
|-----|-----|-----|-----|-----|-----|
| subitem not at all important | ○   | ○   | ○   | ○   | ●   |

Does your paper address subitem 1b-iv?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Results: Recruitment commenced in July 2018 and the results are expected to be submitted for publication in late 2020". No further results are available as this is a protocol paper

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials
Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

|     | 1   | 2   | 3   | 4   | 5   |
|-----|-----|-----|-----|-----|-----|
| subitem not at all important | ○   | ○   | ○   | ○   | ●   |

Does your paper address subitem 1b-v?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No results are available as this is a protocol paper

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution
Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

|     | 1   | 2   | 3   | 4   | 5   |
|-----|-----|-----|-----|-----|-----|
| subitem not at all important | ○   | ○   | ○   | ○   | ●   |
Does your paper address subitem 2a-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

“A targeted early intervention that provides optimal treatment for cannabis use and PEs could reduce the risk of these adverse outcomes, and their associated personal, social, economic, and health costs’...’Although systematic reviews found web/mobile-based programs for people with psychosis were highly acceptable, usable, and engaging, and reduced the severity of psychotic symptoms and risk of transition to psychotic disorders among help-seeking patients at ultra-high-risk for psychosis [40, 41], no web-based early interventions for PEs have been tested in a randomized controlled trial (RCT) to date.’...’To address this gap, we developed the standalone Keep it Real, a web-based program targeting cannabis use and PEs in young people.’

2a-ii) Scientific background, rationale: What is known about the (type of) system
Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropriate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

|   | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| subitem not at all important |   |   |   |   |   |
| essential |   |   |   |   |   |

Does your paper address subitem 2a-ii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

‘Young adults aged 18 to 24 years (23%) have the highest rates of past year cannabis use in Australia’...’Cannabis use has been strongly linked to psychotic experiences (PEs)’...’Together, this research indicates that cannabis use is a preventable risk factor for PEs’. ‘This control condition was designed to provide participants with access to the type of web-based information they may have found naturally online.’

2b) In INTRODUCTION: Specific objectives or hypotheses
Consent to Publish

I consent to the publication of this document.

[Signature]

Date: 21/11/2019
Does your paper address CONSOR subitem 3b-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NA: This is a protocol paper

3b-i) Bug fixes, Downtimes, Content Changes
Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

Does your paper address subitem 3b-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NA: This is a protocol paper

4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes

4a-i) Computer / Internet literacy
Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

Does your paper address subitem 4a-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

4a (i) "They are also required to have internet access and to provide a mobile number and email address*

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:
Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.
Does your paper address subitem 4a-ii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

4a (ii) "The baseline and followed up assessments are self-completed online. Participant contact details (name, email address, mobile number) as well as the IP address of the respondent will be manually checked to identify repeat or duplicate surveys. Participants who give contact details that appear false, for example, multiple similar names or email addresses, will be excluded" 

Does your paper address subitem 4a-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

4a (iii) "A two-step recruitment and consent process will be used. Young people aged 16-25 years, who have used cannabis in the past month will be recruited online via university student emails and posts and paid advertising to social media (e.g., Facebook) and substance use-related websites (e.g., Cannabis Information Service). They are asked to complete an online survey on Cannabis and Psychotic Experiences, and repeat the survey 6 and 12 months later. Young people are asked if they interested in trialling the Keep it Real website as part of the online survey informed consent process, and again at the end of the baseline survey. Those who express interest in trialing the website and score a minimum of 18 on the CAPE-1, which is indicative of at least 3 PEs 'sometimes' or 1 PE 'nearly always' in the past 3 months, are eligible to participate in the RCT."

Does your paper address CONSORT subitem 4b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

| 1 | 2 | 3 | 4 | 5 | essential |
|---|---|---|---|---|-----------|
|   |   | ☐ |   |   |           |

Does your paper address subitem 4b-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

The baseline and follow up assessments are self-completed online

4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants (on eHealth media), as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention. (Not a required item – describe only if this may bias results)

| 1 | 2 | 3 | 4 | 5 | essential |
|---|---|---|---|---|-----------|
| ☐ |   |   |   |   |           |

Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Not required as university affiliation on the consent form is unlikely to bias results.

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and owners

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

| 1 | 2 | 3 | 4 | 5 | essential |
|---|---|---|---|---|-----------|
|   |   | ☐ |   |   |           |

Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

The Keep it Real program was developed by two of the authors. Leanne Hides wrote the program content and oversaw the development of the web-based programs. The program was built by developers employed by the Queensland University of Technology. David Kavanagh reviewed program content and development. Program IP is owned by the university.

5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations...
(e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

| subitem not at all important | 1 | 2 | 3 | 4 | 5 | essential |
|-----------------------------|---|---|---|---|---|-----------|

Does your paper address subitem 5-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

5-iii) Revisions and updating
Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

| subitem not at all important | 1 | 2 | 3 | 4 | 5 | essential |
|-----------------------------|---|---|---|---|---|-----------|

Does your paper address subitem 5-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Keep it Real (Version 2) consists of 7 modules. The first 3 modules target PEs. "These modules were originally developed for the Get Real web-based program for young people with PEs. A small pilot in 12 young people found the program had high levels of acceptability and perceived utility, and resulted in significant reductions in the frequency and level of distress associated with PEs at 3 months follow up [72]."

Modules 4 and 5 target substance use. "Program content was informed by evidence based brief motivational interviewing interventions for cannabis use, including web-based programs [37, 38, 73]. A series of participatory design workshops with young people in residential treatment for substance use problems were also conducted to develop and refine program content.”

“Version 1 of Keep it Real, which was tested in the initial pilot study only targeted cannabis use. Version 2 targets cannabis, alcohol, methamphetamine and heroin use.”

5-iv) Quality assurance methods
Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

| subitem not at all important | 1 | 2 | 3 | 4 | 5 | essential |
|-----------------------------|---|---|---|---|---|-----------|
Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Program content was based on evidence-based face-to-face treatments for PEs and cannabis use. 'The first 3 modules aim to increase the users' ability to identify, understand, and reduce distress associated with PEs. Program content was informed by the Think You're Crazy? Think Again [68] self-help book, based on Morrison's evidence-based CBT treatment for people at 'ultra high risk' for psychosis (including those with PEs) [69-71].'

"Modules 4 and 5 use motivational interviewing techniques to target cannabis, alcohol, methamphetamine and heroin use. Program content was informed by evidence based brief motivational interviewing interventions for cannabis use, including web-based programs [37, 38, 73]." 

5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used

Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

NA as this is a protocol paper

5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.
The URL for the RCT is provided in this ehealth checklist but not the protocol paper as it will change once the RCT is complete and the website becomes open access. It will also be archived.

5-vii) Access
Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained “access to the platform and Internet” [1]. To ensure access for editors/reviewers/readers, consider to provide a “backdoor” login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

| Subitem not at all important | 1 | 2 | 3 | 4 | 5 | Essential |
|-----------------------------|---|---|---|---|---|-----------|

Does your paper address subitem 5-vii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

“Young cannabis users who meet RCT inclusion criteria and consent to participate, are automatically randomized to either the Keep it Real or ICW program, and are sent an email and SMS link to the relevant program. Both programs are accessible via login on any computer, tablet or mobile device with an internet connection. They are password-protected and are sited on parallel, secure servers.”

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework
Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1], whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback” [6]. This also includes a description of communication delivery channels and — if computer-mediated communication is a component — whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

| Subitem not at all important | 1 | 2 | 3 | 4 | 5 | Essential |
|-----------------------------|---|---|---|---|---|-----------|
Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Keep it Real web-based program

The Keep it Real program (Version 2) consists of 7 modules that can be completed in 30-90 minutes over one to three sessions (via login). Version 1 of Keep it Real, which was tested in the initial pilot study only targeted cannabis use. Version 2 targets cannabis, alcohol, methamphetamine and heroin use. Each module ends with a printable summary screen. PEs are targeted first, given young people are more likely to be concerned about PEs than their cannabis use. The first 3 modules aim to increase the users’ ability to identify, understand, and reduce distress associated with PEs. Program content was informed by the Think You’re Crazy? Think Again [69] self-help book, based on Morrison's evidence-based CBT treatment for people at ‘ultra high risk’ for psychosis (including those with PEs) [70-72]. Module 1 defines PEs and provides detailed personal feedback on self-reported PEs, relative to age and gender-specific norms. Module 2 provides information on risk factors for PEs (including cannabis use, trauma, stress, anxiety/depression), psychotic symptoms, and disorders using fact sheets and videos. Module 3 provides information and normative data on different subtypes of PEs and suggests a number of simple CBT techniques for their management. These modules were originally developed for the Get Real web-based program for young people with PEs. A small pilot in 12 young people found the program had high levels of acceptability and perceived utility, and resulted in significant reductions in the frequency and level of distress associated with PEs at 3 months follow up [73]. Modules 4 and 5 use motivational interviewing techniques to target cannabis, alcohol, methamphetamine and heroin use. Program content was informed by evidence based brief motivational interviewing interventions for cannabis use, including web-based programs [37,38,74]. A series of participatory design workshops with young people in residential treatment for substance use problems were also conducted to develop and refine program content. Interactive quizzes on cannabis, alcohol, methamphetamine and heroin use are included to increase substance use knowledge. Young people are also given personal feedback on their substance use and related problems, relative to age and gender-specific norms. Participants can complete and receive normative feedback on the CEQ-I to increase awareness of the relationship between cannabis use and PEs [57]. They are then encouraged to set harm minimization or change goals and develop a plan for achieving them using harm minimization skill and change goal checklists.

Module 6 targets users’ coping skills by providing training in cognitive-behavioural techniques including stress management, problem solving, behavioural activation, and attention control retraining (mindfulness). Module 7 encourages appropriate help seeking for PEs and/or cannabis use and addresses any barriers to doing so.

Participants can track their PEs (CAPE-15), cannabis intoxication effects (CEQ-I), substance use and related problems over time, and receive feedback relative to age and gender-specific norms each time they complete the measures. An interactive graphical summary of their PE, CEQ-I, cannabis, alcohol,
methamphetamine and heroin use and related-problems over various timeframes (self-selected) is also available to increase participants’ awareness of the relationship between their substance use and PEs.

Information Control Website (ICW)
This program delivers the information sheets from the Keep it Real program in a 4-module web-based format including: (i) What are weird experiences?; (ii) How does cannabis affect me?; (iii) How does other substance use affect me?; and (iv) Should I seek help?. Further reading sheets are also available from a “Fact Sheets” menu containing: (i) What is psychosis?; (ii) Am I at risk of developing psychosis?; (iii) What is schizophrenia?; (iv) What is Bipolar Disorder?; and (v) Facts about cannabis/alcohol/amphetamines/heroin. This control condition was designed to provide participants with access to the type of web-based information they may have found naturally online. It does not provide personal feedback from assessments or normative feedback on substance use or PEs at baseline or follow up. No information is given on how to manage PEs; nor do the resources focus on building motivation to change substance use or increasing users’ understanding of the relationship between their substance use and PEs.

5-ix) Describe use parameters
Describe use parameters (e.g., intended “doses” and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

| subitem not at all important | 1 | 2 | 3 | 4 | 5 | essential |
|-----------------------------|---|---|---|---|---|-----------|

Does your paper address subitem 5-ix?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

“The Keep it Real program (Version 2) consists of 7 modules that can be completed in 30-90 minutes over one to three sessions (via login).”

5-x) Clarify the level of human involvement
Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as “type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered”. It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

| subitem not at all important | 1 | 2 | 3 | 4 | 5 | essential |
|-----------------------------|---|---|---|---|---|-----------|

Does your paper address subitem 5-x?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

“Both programs are self-guided (fully automated) and all website modules are unlocked and can be accessed by the user at any time”

5-xi) Report any prompts/reminders used
Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).
Does your paper address subitem 5-xi? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"SMS reminders to access both programs will be sent 7, 14, and 21 days after Baseline."

5-xii) Describe any co-interventions (incl. training/support)
Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as eHealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

Does your paper address subitem 5-xii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NA - this is a standalone intervention

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Does your paper address CONSORT subitem 6a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed
If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].
Does your paper address subitem 6a-i?
Copy and paste relevant sections from manuscript text

The survey was open but only people who indicated they met inclusion criteria were able to complete the full survey. "The trial has ethical approval". A two-step recruitment and informed consent process will be used. The study information sheet reported: how long it would take to complete the survey, how and where data are stored, the names of the investigators, the purpose of the study and how data is protected. Online surveys were developed and delivered using Qualtrics software and were thoroughly tested to ensure their accuracy prior to use. Only valid and reliable measures were used (see Measures section for further information). Participants will be recruited via university student emails or online posts to social media (e.g., Facebook) and substance use-related websites (e.g., Cannabis Information Service) containing a link to the survey. They were asked to complete an online survey on Cannabis and Psychotic Experiences, and repeat the survey 6 and 12 months later: “All baseline, 6- and 12-month survey completers will be entered in a draw to win one out of ten $100 gift vouchers.” RCT “participants are reimbursed $20 for completing each follow-up survey (maximum of $80)”. A timeframe for data collection is not specified as recruitment and data collection are ongoing at this protocol stage of the project. The questionnaire order in the online survey is not randomized, but the primary outcome variables were completed first. Adaptive questioning was only used if the original questionnaires had a skip structure. Item order was not randomized in questionnaires to preserve the psychometric properties of the scales. A maximum number of 28 items (in one measure) per page were included in the online survey. The response scale was visible at all times. Completeness checks were conducted such that all items had to be answered before the online survey could be submitted. All valid survey responses will be analysed for Intent to Treat (ITT) purposes. Survey responses will be checked to determine if there was sufficient variability in responses at two points: (1) Data collection: Survey responses will be visually inspected to identify participants who reported the same response within scales. Particular attention is paid to reverse scored items. Participants with suspect data will be contacted via telephone to clarify the relevant responses, or if necessary, will be asked to attempt the survey again; (2) Data cleaning: Item variability within scales will be checked again. Participants with no variability in their responses on more than one scale will be marked as invalid. The time it took participants to complete the survey will also be checked to ensure it was not completed in less than 10-15 minutes.

Participants are able to review and change their answers using a back button in the online survey. To prevent multiple entries into the study from the same individual: “Participant contact details (name, email address, mobile number), as well as the IP address of the respondent will be manually checked identify repeat or duplicate surveys. Participants who give contact details that appear false, for example, multiple similar names or email addresses, will be excluded.” To prevent multiple responses to the same survey: participants will be sent a unique link for all follow-up surveys. Participation and completion rates for the baseline and follow up surveys as well as the number of modules accessed/completed in each web-based program will be monitored and reported in the RCT paper.
6a-ii) Describe whether and how “use” (including intensity of use/dosage) was defined/monitored/monitored

Describe whether and how “use” (including intensity of use/dosage) was defined/monitored/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

---

Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

“Participant 'backend' usage data will be automatically captured by the website, including logins, modules accessed/completed, inserted text and dates of data entry.”

---

6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained

Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).

---

Does your paper address subitem 6a-iii?

Copy and paste relevant sections from manuscript text

“(iv) Website evaluation: The 26-item eHealth Rating Scale which is based on the Mobile App Rating Scale (MARS) [68] user version, will be utilized to measure the usability, engagement, aesthetics, information quality and perceived impact of the web programs at 3 months follow-up. Participants are also asked to provide written feedback on the website.”

---

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NA: This is a protocol paper

7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed
7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

| Subitem not at all important | 1 | 2 | 3 | 4 | 5 | Essential |
|------------------------------|---|---|---|---|---|-----------|

Does your paper address subitem 7a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this”) to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"To measure a moderate effect size of \( f = .20 \), alpha (\( \alpha \)) set at 0.025 and power set at 0.95, we would require 191 participants per group (a total of 382). If baseline covariates accounting for about 40% of the variability in the outcome model were included in the calculations, then we would have 0.99 power to detect a small-moderate treatment effect. We predict a 20-30% attrition rate at 12 months based on our pilot data and previous work and will therefore need to randomize a total of 498 participants."

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this”) to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

NA: This is a protocol paper

8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this”) to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"A computerized random number sequence generator incorporating random permuted blocks will be used to allocate participants to (i) Keep it Real or (ii) ICW."

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this”) to indicate direct quotes from your manuscript, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Stratification will be by cannabis usage (daily or less), sex, age (16-20 years, 21-25 years) and psychosis screen result (present vs. not present)."
9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"The randomization sequence is concealed within the secure website and the allocation is automatically released when full eligibility criteria is met."

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"A computerized random number sequence generator"

"Eligible participants are automatically sent the consent form for the RCT, and those who provide consent (via a checkbox) are randomized and sent an email and SMS link to either the Keep it Real web-based program or information only control website."

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

| subitem not at all important | 1 | 2 | 3 | 4 | 5 | essential |
|-----------------------------|---|---|---|---|---|-----------|

Does your paper address subitem 11a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Participants "are blind to which website-program they are allocated to. "Those in the RCT are automatically sent follow-up surveys at 3, 6, 9, and 12 months post baseline via SMS and email. Non-completers will be contacted via telephone by outcome assessors blind to treatment allocation to remind them to complete the survey online or over the phone"

"The trial statistician will be blind to treatment group allocation".
11a-ii) Discuss e.g., whether participants knew which intervention was the “intervention of interest” and which one was the “comparator”

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the “intervention of interest” and which one was the “comparator”.

Does your paper address subitem 11a-ii?  
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants were automatically randomized and sent a link to the website program they were allocated to. They were not informed which program was the “intervention of interest” and which one was the “comparator”. The Participant Information and Consent Form stated: You will be provided a link to a website via email. You have an equal chance of being randomized to receive either the (1) Keep it Real online program or (2) The Keep it Real Information-based online program. Both programs provide information on psychotic-like experiences, psychosis and cannabis use. They just differ by their level of interactivity. The following information is provided in the protocol paper: “They are not informed which website program they are allocated to, as the study information sheet states: Both programs provide information on PEs, psychosis and cannabis use. They just differ by their level of interactivity.”

11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NA

12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CONSORT subitem 12a? *

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfAFvMrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGl2...
12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

| Subitem not at all important | 1 | 2 | 3 | 4 | 5 | Essential |
|-----------------------------|---|---|---|---|---|-----------|

Does your paper address subitem 12a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Missing data will be handled using full information maximum likelihood estimation and an intent to treat analysis is performed."}

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address CONSORT subitem 12b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This technique can also control for potential confounds (e.g. other drug use and related problems) and examine potential baseline moderators of intervention effects (e.g., age, gender, childhood trauma (CTQ), impulsivity (SUPPS-P), urbanicity, cannabis knowledge, lifetime psychotic disorder)."

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under 'Methods'] (not a CONSORT item)

X26-i) Comment on ethics committee approval

| Subitem not at all important | 1 | 2 | 3 | 4 | 5 | Essential |
|-----------------------------|---|---|---|---|---|-----------|

Does your paper address subitem X26-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The trial has ethics committee approval"
### x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.), and what information was provided (see 4a-ii). See [5] for some items to be included in informed consent documents.

| subitem not at all important | 1 | 2 | 3 | 4 | 5 | essential |
|------------------------------|---|---|---|---|---|-----------|
|                               |   |   |   |   |   |           |

Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

They will recruited online via university student emails and posts and paid advertising to social media (e.g., Facebook) and substance use-related websites (e.g., Cannabis Information Service) containing a link to an online consent form and survey. Snowballing techniques will be used and participants will be offered a reimbursement incentive of $10 for referring a friend to the study. Consentig participants (via a checkbox) self-complete all baseline and follow up assessments online.

### X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

| subitem not at all important | 1 | 2 | 3 | 4 | 5 | essential |
|------------------------------|---|---|---|---|---|-----------|
|                               |   |   |   |   |   |           |

Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

“Weekly meetings monitor project implementation, clinical (incl. study withdrawals, adverse events), and research integrity (incl. data safety). Email or telephone consultations will be used to determine urgent issues, and a record of decision precedents will be kept to ensure consistency. Suicide and psychosis safety protocols identify and manage risk at all survey time-points. Participants with a positive psychosis screen or who report low level of suicide risk (MINI Suicidality scale score of 1-5) receive a message in the online survey and an email providing details of appropriate support services and helplines, and are asked to contact the research team if they have additional questions or would like assistance finding support. Those who report a moderate (Suicidality scale score of 6-9) or high (10+) level of suicide risk are asked if they are receiving adequate support and if their feelings have recently improved (due to the one-month timeframe of the measure). If the participant indicates they do not require further support, no further action is taken. If they request further support, they are called by a research assistant using the call script within 48 hours to assess how further support can be provided. Those who report a suicide plan or have made a suicide attempt within the past month, are contacted by a trained clinical psychologist within 48 hours, who assesses level of risk and helps the participant connect with appropriate supports.”
RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NA: This is a protocol paper. An example flow diagram for the RCT is provided in Figure 1.

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NA: This is a protocol paper.

13b-i) Attrition diagram
Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

Does your paper address subitem 13b-i?
Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NA: This is a protocol paper.

14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
NA: This is a protocol paper. Recruitment is ongoing.

14a-i) Indicate if critical "secular events" fell into the study period
Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"

1 2 3 4 5

subitem not at all important essential

Does your paper address subitem 14a-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NA: This is a protocol paper.

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NA: This is a protocol paper.

15) A table showing baseline demographic and clinical characteristics for each group
NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NA: This is a protocol paper.

15-i) Report demographics associated with digital divide issues
In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

1 2 3 4 5

subitem not at all important essential

Does your paper address subitem 15-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups.

16-i) Report multiple "denominators" and provide definitions
Report multiple "denominators" and provide definitions: Report Ns (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

16-ii) Primary analysis should be intent-to-treat
Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

17a-i) Presentation of process outcomes such as metrics of use and intensity of use
In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).
Does your paper address subitem 17a-i?  
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  
NA: This is a protocol paper.

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b?  
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  
NA: This is a protocol paper.

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18?  
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  
NA: This is a protocol paper.

18-i) Subgroup analysis of comparing only users
A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).  
subitem not at all important | essential
--- | ---
1 | 2 | 3 | 4 | 5

Does your paper address subitem 18-i?  
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  
NA: This is a protocol paper.

19) All important harms or unintended effects in each group
(for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19?  
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  
NA: This is a protocol paper.

19-i) Include privacy breaches, technical problems
Include privacy breaches, technical problems. This does not only include physical 'harm' to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

Does your paper address subitem 19-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Weekly meetings monitor project implementation, clinical (incl. study withdrawals, adverse events), and research integrity (incl. data safety, important harms or unintended effects)."

19-ii) Include qualitative feedback from participants or observations from staff/researchers
Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

Does your paper address subitem 19-ii?
NA: This is a protocol paper.

DISCUSSION

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)
Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

Does your paper address subitem 22-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.
"This study protocol describes a large RCT that will determine if Keep it Real is more efficacious and cost-effective than the minimal web-based information they may otherwise receive."

22-ii) Highlight unanswered new questions, suggest future research

Highlight unanswered new questions, suggest future research.

| subitem not at all important | 1 | 2 | 3 | 4 | 5 | essential |
|-----------------------------|---|---|---|---|---|-----------|

Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Large numbers of young cannabis users report PEs, which increase their risk of developing psychotic, substance use and depressive/anxiety disorders. Current services are failing to engage these young people — and would struggle to meet the need if they did seek help. An effective, safe, low-cost, non-stigmatising accessible intervention is needed. Our pilot data showed the Keep it Real program resulted in substantial reductions in both PEs and cannabis use, and young people found the program engaging and easy to use."

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

| subitem not at all important | 1 | 2 | 3 | 4 | 5 | essential |
|-----------------------------|---|---|---|---|---|-----------|

Does your paper address subitem 20-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"The number of modules in the Keep it Real and ICW programs are not matched, as the ICW program only contains the Keep it Real information sheets. While it could be argued that the smaller amount of content in the ICW may be insufficient to produce an effect, this control condition was designed to control for access to a web-program and the minimal amount and type of information users may otherwise receive online. Nevertheless, it is possible that the overlap in content may wash out any differential treatment effects between the programs. *"
21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

| subitem not at all important | 1 | 2 | 3 | 4 | 5 | essential |
|-----------------------------|---|---|---|---|---|----------|

Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Young people will be asked if they were interested in participating in the RCT prior to receiving feedback on their PEs. While this recruitment strategy will ensure all young people are given the opportunity to participate, it may increase risk of selection bias by potentially excluding those with little insight into their PEs. Nevertheless, the inclusion of people with a lifetime history of a psychotic disorder and the stratification of the randomization based on diagnostic status, may help reduce such risk of bias."

21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

| subitem not at all important | 1 | 2 | 3 | 4 | 5 | essential |
|-----------------------------|---|---|---|---|---|----------|

Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Keep it Real will be freely available and users will have unlimited 24/7 access to the program, including the PE and substance use monitoring and feedback, enabling the user to engage in continuous self-management. The program also has broad applicability as it can be used as a stand-alone treatment or as an adjunct to usual treatment for help-seeking cannabis users with PEs accessing clinical services. Different components of the program can also be used to address cannabis, alcohol, methamphetamine or heroin use, psychotic experiences, cannabis intoxication effects, and to provide coping skills training."
OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Registration: https://www.anzctr.org.au/
ACTRN12618001107213

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? *
Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

NA: This is the protocol paper

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"CYSAR and the LLW group are supported by Commonwealth funding from the Australian Government provided under the Drug and Alcohol Program."

X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the study team towards the system being evaluated
In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

Does your paper address subitem X27-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The Keep it Real program was developed by two of the authors. Leanne Hides wrote the program content and oversaw the development of the web-based programs. The program was built by developers employed by the Queensland University of Technoloov. David Kavanaach reviewed oororam content and
As a result of using this checklist, did you make changes in your manuscript? *
- yes, major changes
- yes, minor changes
- no

What were the most important changes you made as a result of using this checklist?

More details about the recruitment and consent were added

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript? *

5 hours

As a result of using this checklist, do you think your manuscript has improved? *
- yes
- no
- Other:

Would you like to become involved in the CONSORT EHEALTH group?

This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document
- yes
- no
- Other:

Any other comments or questions on CONSORT EHEALTH

Your answer
When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don’t worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit!

Click submit so we have your answers in our database!

SUBMIT

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy

Google Forms